<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770367</url>
  </required_header>
  <id_info>
    <org_study_id>Takeda 07-060</org_study_id>
    <secondary_id>18379</secondary_id>
    <nct_id>NCT00770367</nct_id>
  </id_info>
  <brief_title>Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes</brief_title>
  <official_title>Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana King</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SPECIFIC AIMS

        1. To determine whether pioglitazone will reduce levels of asymmetric
           dimethylarginine(ADMA) in patients with diabetes.

        2. To determine whether nitric oxide(NOx) products are increased with pioglitazone
           treatment.

        3. To determine whether pioglitazone reduces oxidative stress (F2-isoprostanes).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to determine whether treatment with pioglitazone can
      reduce serum levels of asymmetric dimethylarginine (ADMA) in patients with adult diabetes.
      Recent research has found that elevated serum ADMA is associated with increased
      cardiovascular events and mortality, particularly in people with diabetes (Boger 2005,
      Zoccali 2006, Ueda 2007). ADMA, by mediating nitric oxide (NO) availability, may trigger
      pro-atherogenic effects. High plasma concentration of this substance has been associated with
      intima-media thickening, left ventricular hypertrophy and all-cause and cardiovascular
      mortality in patients with end-stage renal disease, and associated with increased
      cardiovascular events in patients with diabetes (Kryzazanowska 2007). The result of higher
      levels of ADMA and reduced output of NO increases vasoconstriction, increases inflammation,
      and interferes with endothelial function. Preliminary studies indicate that pioglitazone may
      reduce ADMA levels, and thus lower cardiovascular risk.Thus, this protocol will test whether
      pioglitazone can reduce ADMA levels in adult patients with diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asymmetric Dimethylarginine (ADMA) Level</measure>
    <time_frame>3 months</time_frame>
    <description>Labs measured micro moles per liter of ADMA levels in participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NOx f2-isoprostanes</measure>
    <time_frame>3 months</time_frame>
    <description>Measured oxidative stress - NOx measured by chemiluminescence detection using the Sievers NOA 280i and f2-isoprostanes are isolated by thin layer chromatography and subjected to a highly sensitive and specific gas chromatography/mass spectroscopy method to measusre the oxidative stress</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Pioglitazone then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take Pioglitazone for the first 12 week period of the study and then take the placebo for the final 12 weeks of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 (other half of participants) volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take the placebo for the first 12 week period of the study and then take the Pioglitazone for the final 12 weeks of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone then Placebo</intervention_name>
    <description>Subjects will take the pioglitazone 30mg tablet daily for 3 months. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take a placebo.</description>
    <arm_group_label>Pioglitazone then Placebo</arm_group_label>
    <other_name>Actos, Glustin, Zactos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo then Pioglitazone</intervention_name>
    <description>Subjects will take the placebo for the first 12 weeks of the study. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take the pioglitazone 30mg tablet daily for 3 months.</description>
    <arm_group_label>Placebo then Pioglitazone</arm_group_label>
    <other_name>Actos, Glustin, Zactos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults age 40--75 years-of-age, non-pregnant

          -  Informed consent

          -  History of type 2 Diabetes Mellitus

          -  Stable weight for the last 3 months (no change greater than +5% of body weight)

          -  ADMA &gt; 0.50 µM/L (mean of non-diabetic reference group) (Devangelio 2007)

          -  On stable medical therapy for at least 3 months

          -  A working telephone

        Exclusion Criteria:

          -  Any history of known coronary heart disease, including a history of congestive heart
             failure, myocardial infarction, coronary re-vascularization, or stroke

          -  Pregnancy

          -  Chronic kidney disease, serum creatinine &gt;2.0mg/dl, chronic liver disease, or
             uncontrolled hypertension (&gt;160/100).

          -  Current participation in a formal weight loss program or planning to start such a
             program during the next 3 months

          -  Collagen vascular disease, infection, or other inflammatory condition

          -  Electrocardiogram (EKG) evidence of ischemia or infarction

          -  Macular edema (swelling of the back of the eye), recent excessive weight gain (over 5%
             of weight in 30 days), elevated liver function tests &gt; 2.5 X the upper limit, or
             history of osteoporosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dana E King, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Family Medicine, MUSC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <results_first_submitted>July 8, 2010</results_first_submitted>
  <results_first_submitted_qc>October 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2010</results_first_posted>
  <last_update_submitted>December 2, 2011</last_update_submitted>
  <last_update_submitted_qc>December 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Dana King</investigator_full_name>
    <investigator_title>Vice Chair and Proffessor</investigator_title>
  </responsible_party>
  <keyword>Cardiovascular risk</keyword>
  <keyword>biological markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>N,N-dimethylarginine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>medical clinic, 36 participants recruited</recruitment_details>
      <pre_assignment_details>After informed consent, a laboratory specimen will be obtained at the visit, including a pregnancy test (if indicated), and the screening ADMA level. This information will be used to determine study eligibility. Screened participants will be eligible if their ADMA &gt; 0.50 μM/L. If not eligible would be excluded from study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone</title>
          <description>This is the analysis period during which participants took Pioglitazone.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>The analysis period during which participant took the placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period of 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone</title>
          <description>This is the analysis period during which participants took Pioglitazone.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>The analysis period during which participant took the placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.2" spread="1.89"/>
                    <measurement group_id="B2" value="55.7" spread="2.42"/>
                    <measurement group_id="B3" value="54" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>NOx f2-isoprostanes</title>
        <description>Measured oxidative stress - NOx measured by chemiluminescence detection using the Sievers NOA 280i and f2-isoprostanes are isolated by thin layer chromatography and subjected to a highly sensitive and specific gas chromatography/mass spectroscopy method to measusre the oxidative stress</description>
        <time_frame>3 months</time_frame>
        <posting_date>12/2010</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Asymmetric Dimethylarginine (ADMA) Level</title>
        <description>Labs measured micro moles per liter of ADMA levels in participants.</description>
        <time_frame>3 months</time_frame>
        <population>Recruited 36 participants per randomization.1st analysis is serum Asymmetric Dimethylarginine ADMA at 12 weeks b/w groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>This is the analysis period during which participants took Pioglitazone.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The analysis period during which participant took the placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Asymmetric Dimethylarginine (ADMA) Level</title>
          <description>Labs measured micro moles per liter of ADMA levels in participants.</description>
          <population>Recruited 36 participants per randomization.1st analysis is serum Asymmetric Dimethylarginine ADMA at 12 weeks b/w groups.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".80" lower_limit=".75" upper_limit=".85"/>
                    <measurement group_id="O2" value=".75" lower_limit=".71" upper_limit=".79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A twosample comparison of mean treatment differences conducted using a pre-determined significance level of alpha level &lt;0.05. 2 a comparison of means for NOx levels at 12 weeks b/w groups. 3 on the change F2-isoprostanes at 12 weeks b/w groups.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence.</non_inferiority_desc>
            <p_value>.37</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.05</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone</title>
          <description>This is the analysis period during which participants took Pioglitazone.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>The analysis period during which participant took the placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dana King MD</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-8112</phone>
      <email>kingde@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

